Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (361-370 of 703) with videos related to

Pageof 71
Sort By:
Nature Communications|December 3, 2014
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanomaGeorgina V Long, Carina Fung, Alexander M Menzies, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyHelen Dearden, Lewis Au, Daniel Y Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
JAMA Network Open|August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected MelanomaRachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2017
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK InhibitorsHojabr Kakavand, Robert V Rawson, Gulietta M Pupo, et al.
British Journal of Cancer|October 7, 2020
The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrenceRoy Rabbie, Peter Ferguson, Kim Wong, et al.
British Journal of Cancer|March 22, 2017
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''Samantha Bowyer, Prashanth Prithviraj, Paul Lorigan, et al.
Oncoimmunology|January 27, 2017
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMarcel A Deken, Jules Gadiot, Ekaterina S Jordanova, et al.
JCO Precision Oncology|March 12, 2026
Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL StudyAndrea Boutros, Matteo S Carlino, Raja Chaganti, et al.
Genome Medicine|May 26, 2026
Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypesEva R Shteinman, Grace H Attrill, Nigel G Maher, et al.
Pageof 71

Showing results (361-370 of 703) with videos related to

Sort By:
Pageof 71
Nature Communications|December 3, 2014
Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanomaGeorgina V Long, Carina Fung, Alexander M Menzies, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapyHelen Dearden, Lewis Au, Daniel Y Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.
JAMA Network Open|August 3, 2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected MelanomaRachel S Goodman, Aleigha Lawless, Rachel Woodford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2017
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK InhibitorsHojabr Kakavand, Robert V Rawson, Gulietta M Pupo, et al.
British Journal of Cancer|October 7, 2020
The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrenceRoy Rabbie, Peter Ferguson, Kim Wong, et al.
British Journal of Cancer|March 22, 2017
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''Samantha Bowyer, Prashanth Prithviraj, Paul Lorigan, et al.
Oncoimmunology|January 27, 2017
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanomaMarcel A Deken, Jules Gadiot, Ekaterina S Jordanova, et al.
JCO Precision Oncology|March 12, 2026
Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL StudyAndrea Boutros, Matteo S Carlino, Raja Chaganti, et al.
Genome Medicine|May 26, 2026
Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypesEva R Shteinman, Grace H Attrill, Nigel G Maher, et al.
Pageof 71